SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In ...

SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.

The company said that 72 out of the prespecified 80 deaths required to trigger the final analysis have now occurred as of Dec ...

If you want to know who really controls SELLAS Life Sciences Group Inc (NASDAQ:SLS), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, ...

The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.

NEW YORK, May 26, 2021 /PRNewswire/ -- Bruderman Brothers, LLC ("Bruderman Brothers"), is pleased to announce the successful sale of HealthEx Corporation ("HealthEx") to Associated Courier, Inc. ("ACI ...